Back to Search
Start Over
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer.
- Source :
-
Cancer Investigation . Mar2012, Vol. 30 Issue 3, p231-235. 5p. 1 Chart, 3 Graphs. - Publication Year :
- 2012
-
Abstract
- We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL ( p ==.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p ==.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 07357907
- Volume :
- 30
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Cancer Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 71959801
- Full Text :
- https://doi.org/10.3109/07357907.2012.656862